World’s Top Ten Cancer Drugs by 2020

Click sobre imagen para ampliar

According to the World Health Organization, around 8.2 million people die from cancer every year and it comprises an estimated 13% of all deaths worldwide. It is also predicted by the WHO that there will be a 70% increase in new cases of cancer in the next two decades. Fortunately, many pharma and biotech companies are now focusing on this need. 

A 2016 statistical report from Statista (www.statista.com) has displayed the projected top 10 oncology drugs worldwide by 2020. The drugs are ranked by revenue. The list is expected to be headed by Revlimid, a cancer drug manufactured by U.S.-based company Celgene, forecasted to manufacture five of the leading six cancer drugs by 2020. Here are the top oncology medicines in detail: 

1. Revlimid (Celgene) Generic Name: Lenalidomide Projected Sales in 2020: $10,110 Million Revlimid is used to treat multiple myeloma and mantle cell lymphoma. It is used also in patients with myelodysplastic syndrome associated with a deletion 5q cytogenetic abnormality 

2. Imbruvica (AbbVie/J&J) Generic Name: Ibrutinib Projected Sales in 2020: $8,213 Million Imbruvica is indicated for chronic lymphocytic leukemia (CLL), chronic lymphocytic leukemia (CLL) with 17p deletion, Waldenström’s macroglobulinemia (WM) and mantle cell lymphoma (MCL) who have received at least one prior treatment. 

3. Avastin (Roche) Generic Name: Bevacizumab Projected Sales in 2020: $ 6,733 Million Avastin is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, platinum-resistant recurrent epithelial ovarian and fallopian tube or primary peritoneal cancer. 

4. Opdivo (BMS) Generic Name: Nivolumab Projected Sales in 2020: $ 6,201 Million Opdivo is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma, metastatic non-small cell lung cancer and advanced renal cell carcinoma. 

5. Xtandi (Medivation) Generic Name: Enzalutamide Projected Sales in 2020: $5,700 Million Xtandi is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 

6. Rituxan (Roche) Generic Name: Rituximab Projected Sales in 2020: $5,407 Million Rituxan is indicated for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, Granulomatosis with Polyangiitis (GPA), (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA). It was one of the world’s 10 best selling drugs last year, hauling in $7.5 billion worldwide but the patent on the drug expires in 2018. 

7. Ibrance (Pfizer) Generic Name: Palbociclib Projected Sales in 2020: $4,722 Million Ibrance is used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) 

8. Perjeta (Roche) Generic Name: Pertuzumab Projected Sales in 2020: $4,669 Million Perjeta is indicated for metastatic breast cancer. It may also be used for HER2-positive, locally advanced, inflammatory, or early stage breast cancer. 

9. Herceptin (Roche) Generic Name: Trastuzumab Projected Sales in 2020: $4,573 Million Herceptin is used in the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. It is also used in metastatic breast cancer and in gastric cancer. The patent in 2019 in the United States. 

10. Keytruda (Merck) Generic Name: Pembrolizumab Projected Sales in 2020: $3,560 Million Merck’s immunotherapy Keytruda is indicated in patients with unresectable or metastatic melanoma and metastatic non-small cell lung cancer.

(Ver)